The impact of a nationwide introduction of new drugs and a treatment protocol for glaucoma on the number of glaucoma surgeries

Journal of Glaucoma

Volumn 14, Issue 3, 2005, Pages 239-242

  Van Der Valk, Rikkert ^a   Schouten, Jan S A G ^a   Webers, Carroll A B ^a   Beckers, Henny J M ^a   Van Amelsvoort, Ludovic G P M ^a   Schouten, Hubert J A ^a   Hendrikse, Fred ^a   Prins, Martin H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Drug therapy; Filtering surgery; Ocular hypertension; Open angle glaucoma; Trend analysis

Indexed keywords

ANTIGLAUCOMA AGENT;

ADULT; AGED; ARTICLE; CATARACT EXTRACTION; CLINICAL PROTOCOL; DRUG COST; FEMALE; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; SHUNTING; STATISTICAL ANALYSIS; TRABECULECTOMY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION; FEMALE; FILTERING SURGERY; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NETHERLANDS; OCULAR HYPERTENSION; PRESCRIPTIONS, DRUG;

EID: 18744398750     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000159121.11371.5f     Document Type: Article

References (28)

1. Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108:1023-1031.
2. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41(Suppl 1):S39-S47.
3. Adamsons IA, Polis A, Ostrov CS, et al. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group. J Glaucoma. 1998;7:395-401.
4. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82-87.
5. Shapiro S, Fraunfelder FT. Acetazolamide and aplastic anemia. Am J Ophthalmol. 1992;113:328-330.
6. Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89:76-80.
7. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Sum Ophthalmol. 2001;45(Suppl 4):S361-S368.
8. Netland, PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
9. Goldberg I. Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;11:275.
10. Ziekenfondsraad. Protocol Gebruik Glaucoommiddelen. Amstelveen: Ziekenfondsraad; 1999: 1-16.
11. European Glaucoma Society E. Terminology and Guidelines for Glaucoma. 1998.
12. Cleveland WS, Devlin SJ, Grosse E. Regression by local fitting: methods, properties, and computational algorithms. J Econom. 1988;37:87-114.
13. Gilbert CM, Brown RH, Lynch MG. The effect of argon laser trabeculoplasty on the rate of filtering surgery. Ophthalmology. 1986;93:362-365.
14. Paikal D, Yu F, Coleman AL. Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998. Ophthalmology. 2002;109:1372-1376.
15. Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma. 2004;13:221-226.
16. Bateman DN, Clark R, Azuara Blanco A, et al. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol. 2002;86:551-554.
17. Bateman DN, Clark R, Azuara Blanco A, et al. The impact of new drugs on management of glaucoma in Scotland: observational study. BMJ. 2001; 323:1401-1402.
18. Leske MG, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121:48-56.
19. Strahlman ER, Vogel R, Tipping R, et al. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology. 1996;103:1283-1293.
20. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899-902.
21. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82:1249-1253.
22. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
23. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12-16.
24. Gurwitz JH, Yeomans SM, Glynn RJ, et al. Patient noncompliance in the managed care setting. The case of medical therapy for glaucoma. Med Care. 1998;36:357-369.
25. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711-716.
26. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle glaucoma. Br J Ophthalmol. 1983;67:46-49.
27. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26:233-236.
28. Konstas AG, Maskaleris G, Gratsonidis S, et al. Compliance and viewpoint of glaucoma patients in Greece. Eye. 2000;14:752-756.